J. J. Molenaar

Anti-cancer compound screening identifies Aurora Kinase A inhibition as a means to favor CRISPR/Cas9 gene correction over knock-out

This study screens cancer drugs to find those that enhance HDR over NHEJ in CRISPR gene editing, identifying Aurora kinase A inhibitors as promising candidates.

Blocking MIF secretion enhances CAR T-cell efficacy against neuroblastoma

This study identifies MIF as a key immunosuppressive factor in neuroblastoma that inhibits CAR T-cell efficacy, showing that blocking MIF enhances T-cell activation and therapeutic potential.

Functional avidity of anti-B7H3 CAR-T constructs predicts antigen density thresholds for triggering effector function

The paper evaluates how the functional avidity of anti-B7H3 CAR-T constructs relates to their ability to trigger effector function against tumors with varying antigen density.

Complex structural variation is prevalent and highly pathogenic in pediatric solid tumors

The paper identifies prevalent and pathogenic complex structural variations in pediatric solid tumors, linking them to adverse clinical outcomes and potential therapeutic targets.

Multi-dimensional profiling of hepatoblastomas and patient-derived tumor organoids uncovers tumor subpopulations with divergent WNT activation profiles and identifies pan-hepatoblastoma drug sensitivities

This study identifies two hepatoblastoma subtypes with distinct WNT activation profiles and discovers drug sensitivities in patient-derived tumor organoids.

Two opposing gene expression patterns within ATRX aberrant neuroblastoma

The paper identifies two opposing gene expression patterns in ATRX-aberrant neuroblastoma models, suggesting distinct molecular mechanisms and treatment implications.

Mesenchymal tumor organoid models recapitulate rhabdomyosarcoma subtypes

This study generates tumor organoid models of rhabdomyosarcoma subtypes that closely resemble original tumors and can be used for drug screening and genetic modification.

Loss of p16INK4a in neuroblastoma cells induces shift to an immature state with mesenchymal characteristics and increases sensitivity to EGFR inhibitors

RRM2 is a target for synthetic lethal interactions with replication stress checkpoint addiction in high-risk neuroblastoma

This study identifies RRM2 as a therapeutic target in high-risk neuroblastoma, showing that combined RRM2 and CHK1 inhibition synergistically reduces tumor growth.

PPM1D is a neuroblastoma oncogene and therapeutic target in childhood neural tumors.

This study identifies PPM1D as an oncogene and therapeutic target in neuroblastoma by showing its role in p53 inactivation and tumor growth.

Tumor to normal single cell mRNA comparisons reveal a pan-neuroblastoma cancer cell

The paper compares tumor and normal single-cell mRNA data to show neuroblastoma cells resemble fetal sympathoblasts across diverse samples.

MEK inhibition causes Bim stabilization and sensitivity to Bcl2 family member inhibitors in RAS-MAPK mutated neuroblastoma

The paper identifies MEK inhibition combined with BCL2 family inhibitors as a potent treatment for RAS-MAPK mutated neuroblastoma by stabilizing Bim and increasing sensitivity to Bcl2 inhibitors.